Y-9738

Y-9738 is a hypolipidemic agent.

Signaling Pathways >> Others >> Others

Research Areas >> Cardiovascular Disease

Y-9738 is a hypolipidemic agent. At 100 mg/kg Y-9738 lowers the cholesterol level by 36% and clearly diminishes the intensity of the β-lipoprotein band with a tendency for the α-lipoprotein band to be intensified. Y-9738 causes a dose-dependent decrease in serum cholesterol, triglyceride and heparin-precipitable β-lipoprotein cholesterol. Furthermore, Y-9738 reduces the intensity of the β-lipoprotein band shown by electrophoresis, and increases that of the α-lipoprotein band[1].

Male Sprague-Dawley rats are used in this work. Rats (140 to 180 g) are fed a high cholesterol diet for 10 days. This diet contains 1% cholesterol, 0.2% sodium cholate and 5% olive oil. Y-9738 is orally administered to the animals once a day throughout the experimental period. All animals are starved overnight (about 20 h) after the last treatment and sacrificed by carotid incision. Blood and liver are collected for lipid analysis[1].

[1]. Kobayakawa T, et al. Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent. Atherosclerosis. 1978 Jul;30(3):219-25.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline